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ARTICLE
Epidemiology
Trends and projections in adenocarcinoma and squamous cell
carcinoma of the oesophagus in England from 1971 to 2037
Judith Offman1, Francesca Pesola1 and Peter Sasieni1,2
BACKGROUND: The aim of this study was to assess the incidence and trends of oesophageal adenocarcinomas (OACs) and
squamous cell carcinomas (OSCCs) in England from 1971 to 2037.
METHODS: Data on 220,026 oesophageal cancers diagnosed in England between 1971 and 2013 were extracted. Multiple
imputation was used to predict morphology data were missing. Incidence rates were modelled and extrapolated to 2037 using
age–period-cohort models.
RESULTS: The OAC age-standardised incidence rate (ASRs) increase was greatest from 1972 to 1992 (from 4.8 to 12.3 for men and
1.1 to 3 per 100,000 for women) and slowed from 1992 to 2012 (with an increase to 17 for men and 3.8 per 100,000 for women).
OSCCs rates decreased from 7.5 to 4.9 from 1972 to 2012 for men. For women, ASRs increased from 5.5 to 5.9 between 1972 and
1992 and then decreased to 4.7 per 100,000 until 2012. Rates until 2032 are predicted to stay stable for OACs and further decrease
for OSCCs.
CONCLUSIONS: Imputing missing morphology allowed accurate and up-to-date estimates of trends and projections. We observed
a slowing down of the increase in OAC ASRs and an overall decrease in OSCC ASRs.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0047-4
INTRODUCTION
There has been a dramatic rise in the incidence of oesophageal
cancer in the developed world over the last 30 years making it
now the 8th most common cancer worldwide.1 Furthermore, it has
a dismal prognosis with age-standardised net survival being less
than 50% at 1-year and less than 20% at 5-years.2 The vast
majority of oesophageal cancers occur as either squamous cell
carcinomas (OSCCs) or adenocarcinomas (OACs).3 In 2012, OSCCs
occurred most commonly in South-Eastern and Central Asia,
whereas the highest incidence of OACs were in high income
countries, speciﬁcally Northern and Western Europe, North
America, and Oceania.1 The highest incidence of OACs worldwide
occurred in the UK. Furthermore, the incidence of OACs has
increased dramatically in the last 30 years in some populations,
whereas the incidence of OSCCs has decreased.4–6
The natural histories of OACs and OSCCs differ substantially.
OSCCs usually arise from the stratiﬁed squamous epithelial lining
in the upper two thirds of the oesophagus, and the main risk
factors are smoking and alcohol.7 OACs, on the other hand,
mainly develop in the lower third of the oesophagus originating
from Barrett’s mucosa. Barrett’s oesophagus (BO), a complication
of gastro-oesophageal reﬂux disease (GORD), predisposes
patients to OAC, but the risk of malignant progression is low.8,9
In addition, other factors like obesity have been linked with
OACs.3,10 Acid suppression using either proton pump inhibitors
(PPIs) or H2 receptor antagonists (H2RAs) are the main treatments
used in the management of GORD, and use of PPIs have been
found to reduce the risk of malignant progression from Barrett’s
to OAC.11
Classiﬁcation of these different cancer types is based on
morphology; however, morphology has frequently been missing
from UK cancer registry records, especially for cancers diagnosed
pre-1990, but also for later time periods.12,13 The aim of this study
was to assess the incidence and trends of OACs and OSCCs in
England from 1971 (when the earliest data are available) to 2013
using an age–period-cohort (APC) model after estimating missing
morphology, and to estimate the future burden until 2037. Several
groups have estimated trends and future projections of OAC and
OSCC rates using APC models. However, they have not allowed for
trends in cancers with unrecorded morphology. Here we use
multiple imputation for cancers with missing morphology to more
accurately estimate trends and projections. Furthermore, due to
the linear dependence of age, period, and cohort in the APC
model, it is not possible to identify the separate impact of age,
period, and cohort effects. We explore the impact of simpler
models as well as reallocation of the non-identiﬁable linear effect
to better understand how these age, period, and cohort effects
inﬂuenced previous and, therefore, will inﬂuence future OAC and
OSCC trends. Understanding current trends and projecting future
burden of both OAC and OSCC will play a key role in planning the
delivery of cancer services. Speciﬁcally, as OACs and OSCCs have
different risk factors, understanding the trends for these two
subtypes separately will allow planning suitable cancer prevention
interventions.
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MATERIALS AND METHODS
Cancer registration and population data
Aggregate data on all available records of malignant cancers of
the oesophagus diagnosed in England between 1971 and 2013
were provided by the Public Health England (PHE) Ofﬁce of Data
Release. Cancer data were provided by single year of diagnosis,
sex and 5-year age-group. From 1971 to 1990 the cancer
registries used the International Classiﬁcation of Diseases
Edition 9 (ICD-9) codes to record anatomical categories. From
1991 onwards the 10th Edition (ICD-10) has been used.14 The
ICD-9 and ICD-10 codes for the anatomical sub-sites respectively
are: cervical (150.0/C15.0), thoracic (150.1/C15.1), abdominal
(150.2/C15.2), upper third (150.3/C15.3), middle third (150.4/
C15.4), lower third (150.5/C15.5), overlapping lesion (150.8/
C15.8) and unspeciﬁed (150.9/C15.9). Mid-year population
estimates 15 and 2012-based population projections up to
2037 16 for England were obtained from the Ofﬁce for National
Statistics.
For cancers diagnosed from 1971 to 1990 cancer morphology
types were recorded based on the Manual Of Tumour Nomen-
clature and Coding (MOTNAC) 17,18 or the ﬁrst edition of the
International Classiﬁcation of Diseases for Oncology (ICD-O-1).19
The second and third editions of the International Classiﬁcation of
Diseases for Oncology (ICD-O-2 and ICD-O-3) 20,21 have been used
from 1991 onwards. Where ICD-O codes had been used
morphology types were deﬁned as follows; OSCCs: 8050–8078
and 8083–8084; OACs: 8140–8141, 8143–8145, 8190–8231;
8260–8263, 8310, 8410, 8480–8490, 8559–8551, 8570–8574, and
8576. For cancers with missing morphology information multiple
imputation using a multinomial logistic regression model was
used to predict the probability of morphology categories: OAC,
OSCC or other (More details on multiple imputation methods can
be found in the Supplementary Appendix Methods Section 1).
Statistical analysis
Cancer incidence rates were modelled and extrapolated to 2037
ﬁtting separate models for OACs and OSCCs by sex using the APC
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Fig. 1 Incidence rates for all oesophageal cancers combined and OACs and OSCCs separately for men and women in England (log scale). a
Annual and modelled incidence rates of all recorded malignant oesophageal cancers from 1971 to 2013. b Annual and modelled OAC
incidence rates including cancers with estimated morphology for men and women from 1971 to 2013 and projected rates until 2037. c Annual
and modelled OSCC incidence rates including cancers with estimated morphology for men and women from 1971 to 2013 and projected
rates until 2037. Dots / triangles represent observed rates; lines represent modelled rates using the APC model. ASR age-standardised
incidence rates, ESP European standard population, OAC adenocarcinoma, OSCC squamous cell carcinoma
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model as described previously.22,23 In brief, the basic APC model
is:
λ(age, period)= g−1{ƒA(age)+ ƒP(period)+ ƒC(cohort)}
where λ is the incidence rate as a function of age and calendar
period, g is the link function and ƒA, ƒp and ƒC are functions of age,
period (i.e. year of incidence) and cohort (i.e. year of birth),
respectively. Both logarithmic and ‘power-5’ (i.e. g−1(x)=x5 as used
by Møller et al 24) functions were used as the link function g, as
both had previously offered a good ﬁt to site-speciﬁc cancer data
in adult populations.22 Cubic splines were used for the functions
ƒA, ƒp and ƒC as they offer greater ﬂexibility and more realistic
projections under the assumption that changes occur gradually.
Analyses were carried out in Stata 13 using a revised apcspline
command, which allows ﬁtting an age–drift model, which was not
possible in the previous version.23,25 More details on the APC
model and comparisons between age, age–drift (AD), age–period
(AP), age–cohort (AC) and APC models are described in Section 2
of the Supplementary Appendix.
Incidence rates were standardised using the European standard
population to calculate age-standardised rates (ASRs).26
RESULTS
There were 220,026 records of malignant cancers of the
oesophagus diagnosed in England between 1971 and 2013. Of
these, 87,650 had been recorded as OACs (67,505 in men; 20,145
in women) and 69,815 as OSCCs (31,853 in men; 37,962 in
women). All other histological subtypes were rare with only 5020
cases (2621 in men and 2399 in women) making up about 2.3% of
all oesophageal cancers. Morphology data were missing for 57,541
cases (32,333 in men and 25,208 in women). As ignoring cancers
with missing morphology would seriously underestimate the true
incidence of OACs and OSCCs, multiple imputation was used.
Imputations took into account age, gender, year of diagnosis,
cancer sub-site and basis of diagnosis—see Section 3 in
the Supplementary Appendix for more details. The distribution
of the three morphology subtypes was very similar when we
included the imputed data compared to the raw data (see
Supplementary Appendix Section 3 Figure S3). Comparisons of
trends and projections with and without MI for both OACs and
OSCCs can be found in Section 4 of the Supplementary Appendix.
Cancers with imputed morphology were included in all of the
following analysis.
The APC model provided a good ﬁt for the data (see Section 5 in
the Supplementary Appendix) and was used for our main analyses
presented below. In addition, alternative models were explored in
a sensitivity analysis.
Oesophageal cancer trends from 1971 to 2013
ASRs for oesophageal cancer (all morphology types) for men have
been increasing most signiﬁcantly between the late 1970s and
mid-2000s, and have started to level off now (Fig. 1a). ASRs for
women have increased until the early 1990s when they stared to
level off and then decreased again slightly since the early 2000s.
However, when looking at OACs and OSCCs separately, opposing
trends can be observed. Observed and modelled incidence rates
for OACs and OSCCs by gender from 1971 to 2013 and projected
rates until 2037 are presented in Fig. 1b, c. Table 1 shows the
number of cases (including imputed cases) and ASRs for 1972,
1992 and 2012 as three-year averages for all ages combined for
men and women.
OAC trends from 1971 to 2013, and projections up to 2037
For OACs the absolute increase in new cases per year between
1972 and 2012 was much greater for men (increase by 3000 new
cases) than for women (781 new diagnoses), but the relative
increase was more similar (about 455% for men and 353% forT
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women) (Table 1 and Fig. 1b). The increase in ASRs was greatest
from 1972 to 1992: male ASRs increased from 4.8 to 12.3 per
100,000 (160%); female from 1.1 to 3.0 (168%). From 1992 to 2012,
the increase in OAC cases was less (both in relative and in absolute
terms) with increases in ASRs of 38% (12.3 to 17.0) for men and
24% (3.0 to 3.8) for women. Trends started levelling off earlier for
women than for men, but then start to increase again towards the
end of the projected period. Based on these trends the incidence
rates of OACs were predicted to stay stable with a slight overall
decrease by 5% for men and a slight overall increase by 6% for
women until 2032.
OSCC trends from 1971 to 2013, and projections up to 2037
OSCC rates decreased overall over the past 40 years for both men
and women. Despite an initial small increase in the number of
squamous cases between 1972 and 1992 in men (Table 1), the
rates for OSCCs in men have been decreasing since 1972
corresponding to an increase in the elderly population. For
women, the ASRs ﬁrst increased (ASR 5.5 to 5.9) from 1972 to 1992
and then decreased from 1992 to 2012. The projected ASRs for
OSCCs indicate that a further reduction in rates is to be seen from
2012 to 2037 (Fig. 1c and Table 1): male ASR projected decrease
from 4.9 to 4.6 per 100,000 (−7%); female from 4.7 to 3.5 per
100,000 (−26%).
OAC and OSCC trends and projections by age group
The increase in OAC rates from 1971 to 2013 was larger in the
older age category for both genders (Fig. 2a): OAC rates for 40–49
year old men only increased from 1.7 to 3.1, whereas rates for 80
+ year olds increased from 23.0 to 84.1 per 100,000. Overall, the
rates for women were much lower, but also increased by age, with
the largest increase for 80+ year old women (5.3 to 24.9 per
100,000). Incidence rates are predicted to level off for all age
groups for both men and women.
The decrease in OSCC rates for men from 1971 to 2013 was
most dramatic in the older age groups (42.3 to 25.1 for 80+ year
olds and 22.9 to 14.7 for 65–79 year olds), compared to a smaller
decrease for the younger age groups (7.1–6.6 for 50–64 year
olds and 1.1–1.0 for 40–49 year olds; Fig. 2b). Rates are predicted
to further decrease slightly for all age groups apart from the
65–79 years olds for whom rates are predicted to increase
slightly to 15.2.
Model comparisons using different age/period/cohort models
To better understand how age, period (year of diagnosis) and
cohort (year of birth) effects impact incidence rates and therefore
predicted future rates further analyses using less complex models
were carried out. More details on the comparison of the APC and
simpler nested models can be found in the Supplementary
Appendix Section 5. For OACs, compared to the standard APC
model, the AP model was found to describe the data equally well
for both men and women (Table S2). We, therefore, chose to
compare two different simpler AP models with the more complex
APC model. We ﬁrstly considered that the AP model would best
describe the natural history of OACs if the linear increase is
captured by a cohort effect (mostly obesity and GERD; Fig. 3a,
dotted line). However, to capture the uncertainty in the AP model,
and to better understand the inﬂuence of the period effect, we
show an alternative solution describing the linear term as a period
effect (Fig. 3a, dashed line). For both we assume that the period
effect is due to the introduction of PPIs causing a reduction in
cancer incidence, so we set the period effect to 0 until 1997, about
10 years after their introduction (Figure S5a). All models ﬁt the
observed data well (Fig. 3a). However, the projections for the
OACs differed more dramatically depending on whether the two
AP models with different options for the linear increase (drift) or
the APC model was used (Fig. 3a). With the AP model describing
the linear increase entirely as a cohort effect (dotted line) the rates
for men are predicted to ﬁrst decrease up to the early 2020s
before they increase again nearing the 2012 rate. Rates for women
on the other hand are predicted to increase again up to 2037. For
the AP model describing the linear term as a period effect (dashed
line) a decrease in rates was observed for men, whereas the rates
for women stayed ﬂat. Therefore, depending on the model, overall
ASRs for men are predicted to decrease between 5 and 38%
(Table S3). For women, ASRs are going to increase ranging by
between 6% to 167%.
For OSCCs, model ﬁt comparisons (Table S2) showed that a
simpler model only including the age effect and a linear
component (age–drift (AD) model) might be sufﬁcient to describe
the data, however, when this model is compared with the ﬁt of
the APC model, it can be seen that the trends estimated using the
AD model (dashed line) did not ﬁt the data as well as using the
APC model (solid line) (Fig. 3b).
DISCUSSION
Main ﬁndings
Using multiple imputations to predict missing morphology
allowed us to more accurately estimate trends for OAC and
OSSC rates based on over 220,000 patients diagnosed over a 42-
year period in England. We found a more than 200% increase in
OACs rates for both genders, with a slightly higher (relative)
increase for men over this time period. The increase in OAC rates
over time was larger for older age groups in both genders.
Predictions of OAC rates up to 2037 differed depending on the
model used: The AP model with the linear increase as a cohort
effect predicted an initial dip in incidence followed by an
increase for men and just a further increase in incidence rates
for women. The APC model on the other hand predicted
incidence rates levelling off. OSCC rates started off higher than
OAC rates for both genders in 1972, then decreased slightly, and
are now signiﬁcantly lower than OAC rates for men. These are
predicted to further decrease.
Meaning of the study
The dramatic increase in OAC rates will most likely have been
caused by a combination of the main risk factors GORD, BO and
obesity. High prevalence of obesity has been linked to high
incidence of OAC 27 and both overweight and obesity rates in
England have been increasing steadily.28 Furthermore, the
incidence of GORD has also risen worldwide in the last 40 years,29
and the prevalence in the Western world is now estimated to
range between 10% and 20%.30 This could have further
contributed towards the high increase in OAC incidence.
If both period and cohort effects are combined in a standard
APC model without any assumptions, the predicted incidence
rates levelled off for both men and women and rates are projected
to stay stable. This projection depends on making “default”
assumptions to identify the period and cohort effects. However, to
better understand how the different risk increasing and risk
reducing factors impact incidence trends we looked at less
complex models (AP) in more details as they offered a good ﬁt to
the data. Firstly, we assumed that levels of obesity, GORD and BO
would vary by birth cohort, i.e. increased for later cohorts, and,
therefore, the contribution of these factors on the increase of OAC
incidence would be in the form of a cohort effect. Secondly, we
assume that the period effect was due to an increase in the use of
PPIs, which have been shown to reduce the risk of OAC by 71% in
a meta-analysis.31 We, therefore, expect the period effect only to
have started to occur from the late 1990s, about 10 years after the
introduction of PPIs. In 1997 3 to 4% of adults in England were
estimated to use PPIs regularly, which increased to 14% in the
2010s.32 For an alternative model to the standard APC model we
hypothesised that until the late 1990s only risks factors acting as
cohort effects (mainly obesity and GORD) inﬂuenced OAC rates,
Oesophageal cancer trends and projections
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which were then counteracted by risk reducing PPIs from the late
1990s. This is supported by the fact that an AC model provided
the best ﬁt for this data up to and including 1996 (not shown).
Hence, we included a period effect from 1997 onwards in the AP
model, which results in a dip in the projected rate for men
between the early 2010s and 2020s, after which the rate increases
again. This would be due to the period effect levelling off due to a
saturation of the number of people taking PPIs and the cohort
effect still increasing over time as environmental risk factors are
still on the increase. For women on the other hand, the OACs
incidence rate keeps increasing, despite a projected levelling off of
the period effect. If the linear increase in rates in the AP model is
only described as a period effect the projected rates drop without
increasing again. This would support the hypothesis that the
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period effect causes a drop in the rates, whereas the cohort effect
results in a further increase in men.
OSCC has been strongly linked with smoking and alcohol.7,33–35
The proportion of both men and women who smoke in England
has decreased from over 42% for men and 36% for women in
1980 to 20% and 19%, respectively in 2010.36 This reduction could
be largely responsible for the reduction in OSCC incidence
observed here. The effect of the reduction in smoking is most
likely a combination of a cohort and period effect, with fewer
people starting to smoke (i.e. cohort effect) and more individuals
quitting (i.e. period effect).
Findings in relation to other studies
The majority of studies investigating OACs and OSCCs trends in
Europe and North America are summarised in Table S4 in Section
6 of the Supplementary Appendix.4–6,37–47 We are only focusing
on the Western world here as both OAC and OSCC trends are very
different in Asia and other low and middle income countries.
These studies report dramatic increases in OAC rates for both
genders for the majority of countries, however, a levelling off was
observed in some of the studies. Two international studies by
Edgren et al. and Arnold et al. found a consistently dramatic increase
in incidence rates of OACs for countries from Australia, North
America, Asia and Europe.4,42 Edgren and colleagues observed a
continuous increase for men and women in England during their
observation period up to 2008, whereas Arnold and
colleagues found a ﬁrst a rapid increase up until the mid-1990s
followed by a slightly slower increase until the late 2000s, more in
line with our observations. They furthermore observed a slowing
increase for Australia from 1990 and slight decrease in incidence for
Denmark from about 2000. Furthermore, Xie and colleagues
reported a slowing down of the increase in OAC in Sweden after
2005.47
Using an APC model Arnold et al. predicted the OAC rates to
further level off until 2030,42 similar to our predictions using the
standard APC model. In the United States (US) three different
mathematical models were used to project the OAC incidence up
to 2030 using observed rates from 1975 to 2010.5 All three
projections showed that the US rates will continue to increase for
both genders until 2030, however, two of the models projected
the rates to slow down in males in the late 2000s. Edgren et al.
also observed that the addition of the drift (linear component) to
age improved the model ﬁt signiﬁcantly for all cancer registry data
including England. In addition, ﬁrst adding the period effect and
then both period and cohort effects further signiﬁcantly improved
their model ﬁt for England.
The majority of studies reported either an initial increase in
OSCC rates followed by decrease or only a decrease in OSCC rates.
This is in line with our ﬁndings for England of decreasing
incidence trends for men for the entire time period and an initial
small increase for women followed by a decrease from early
1990s. Steevens et al. and Arnold et al. on the other hand reported
an increase in OSCC rates in UK from 1982 to 1997 41 and 1990 to
2000 42 respectively. However, they did not include any cancers
with missing morphology records. We observed that the propor-
tion of cancers with missing morphology was higher for earlier
time periods (p < 0.001), see Figure S2. Without including these
cancers we also observed an increase in OSCC rates over this time
period. However, once missing morphology was imputed we
observed a decrease for men and a small increase for women
followed by a decrease from the early 1990s onwards. Arnold et al.
predicted a slight decrease in rates for men and women. Our
predictions are very similar for men, however, for women our
model predicts a fairly steep decrease in rates. This could be due
to the fact that they are only using data from 1988 to 2007,
whereas our predictions are based on records from 1971 to 2013,
and we included all cancers with missing morphology.
Walther and colleagues observed that for women both the AP
and AC models ﬁtted the data well, but for men only the AP model
provided a good ﬁt.46 As data were only available up to 1997 for
this analysis, they might have not have been able to fully see the
impact of a reduction of smoking as occurred in the UK.
Strengths and limitations
Our study has several limitations typical of studies using cancer
registry data. Firstly, site and morphology records for the earlier
years were not as extensive and reliable as in recent years. The
proportion of oesophageal cancers with missing morphology was
as high as 50% in the 1970s. However, by using all available
variables to impute missing morphology, we were able to include
these cancers. This resulted in more accurate cancer trends than
previously reported. Secondly, the proportion of oesophageal
cancer with missing morphology only started to dramatically
decrease in the 1990s reaching below 20% by 2000, which then
drops to less than 10% by 2013. Given that large proportions of
morphology had to be imputed for earlier years, the conﬁdence in
our predictions decreases the further away they get from 2013.
Thirdly, over the time period studied, the way oesophageal and
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stomach cancers have been recorded has changed. With the
increase in interest in OAC as BO became better known in the
1980s, it is possible that cancers of the oesophagogastric junction
(OGJ) have progressively become more likely to be recorded as
oesophageal as opposed to cardia stomach. Furthermore, changes
to the classiﬁcation of cancers in the OGJ in newer editions of the
American Joint Committee on Cancer (AJCC) TNM classiﬁcation
system could have impacted OAC trends. Whereas, the 6th edition
of the AJCC Cancer Staging Manual (2002) speciﬁes that tumours
arising within the OGJ and gastric cardia that only have minimal
involvement (less than 2 cm) in the oesophagus should be
considered primary gastric cancers,48 the 7th edition (2009)
speciﬁes that cancers located in the OGJ or cardia that extend
into the OGJ are to be staged as oesophageal cancers.49 However,
when comparing incidence rates for OACs and cancers of the
cardia, these changes in classiﬁcations of tumour locations
between different editions of the AJCC staging manuals was not
reﬂected in changes in cancer rates (data not shown). It would
have been beyond the scope of this study to further assess the
extent to which misclassiﬁcation or changes in classiﬁcation of
cardia stomach cancer could lead to the observed trends in OAC.
Thirdly, future predictions of cancer rates may depend on future
changes to risk factors, however, data on changes in prevalence of
these risk factors for the time period analysed was not available.
CONCLUSION
Including cancer registry data for England up to 2013 and using
multiple imputation to allow inclusion of cancers with missing
morphology enabled us to include cancers not included in any
previous study, therefore obtaining a more accurate model of
oesophageal cancer trends until 2037. We provide evidence that
the dramatic increase in OAC observed in England since the 1970s
has slowed and is likely to level off. We also observed a more
signiﬁcant decrease in OSCC rates for both genders. We also
present several models taking different effects of risk increasing
and reducing factors into account to allow for the limitations of
the APC model in predicting future trends. The projections of
cancer incidence modelled for OSCCs and OACs presented here
will provide an accurate and up to date baseline for future
planning of cancer resources for both cancer subtypes.
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